Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
155.29B
Market cap155.29B
Price-Earnings ratio
19.88
Price-Earnings ratio19.88
Dividend yield
6.38%
Dividend yield6.38%
Average volume
44.28M
Average volume44.28M
High today
$27.53
High today$27.53
Low today
$27.02
Low today$27.02
Open price
$27.20
Open price$27.20
Volume
37.59M
Volume37.59M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

Pfizer(PFE) stock is priced at $27.40, giving the company a market capitalization of 155.29B. It carries a P/E multiple of 19.88 and pays a dividend yield of 6.4%.

As of 2026-03-25, Pfizer(PFE) stock has fluctuated between $27.02 and $27.53. The current price stands at $27.40, placing the stock +1.4% above today's low and -0.5% off the high.

Pfizer(PFE) shares are trading with a volume of 37.59M, against a daily average of 44.28M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

PFE News

Nasdaq 1h
Is Pfizer Stock a Buy After This Win?

Key Points Pfizer's recent phase 2 win was encouraging, but not yet a slam dunk. The company could make significant clinical and regulatory progress in the ne...

Is Pfizer Stock a Buy After This Win?
24/7 Wall St. 7h
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In By Joey Frenette Published Mar 25, 12:23PM EDT Quick Read Pfizer (P...

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In
Nasdaq 8h
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb BMY recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo. T...

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

TipRanks 11h
Notable open interest changes for March 25th

Tuesday’s total option volume of 56.5 million contracts resulted in net open interest growth of 7.38 million calls and 5.85 million puts. fuboTV (FUBO), NVIDIA...

Simply Wall St 21h
A Look At Pfizer Valuation As Shares Trade Near Recent Levels

Advertisement Pfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and sho...

A Look At Pfizer Valuation As Shares Trade Near Recent Levels
Nasdaq 1d
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme di...

VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
24/7 Wall St. 1d
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial By Joel South Published Mar 24, 10:52AM EDT Quick Read Pfizer (PFE...

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
TipRanks 2d
Pfizer price target raised to $36 from $35 at Guggenheim

Guggenheim raised the firm’s price target on Pfizer (PFE) to $36 from $35 and keeps a Buy rating on the shares. Topline data for Pfizer’s MEVPRO-1 Phase 3 trial...

The Motley Fool 2d
Pfizer Stock Is Doing Something It Hasn't Done Since 2022

Pfizer (PFE 0.74%) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has cl...

Pfizer Stock Is Doing Something It Hasn't Done Since 2022
Simply Wall St 2d
Is Pfizer Offering Value After Its Post Covid Portfolio Shift And Mixed Returns?

Wondering whether Pfizer at a last close of US$26.97 is genuinely offering value or just looks cheap on the surface? This article breaks down what the current p...

Is Pfizer Offering Value After Its Post Covid Portfolio Shift And Mixed Returns?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.